Pharmaceutical tablet with PVP having enhanced drug dissolution rate

摘要

A pharmaceutical tablet is provided herein having an effective dissolution rate. The tablet contains a pharmaceutically-active ingredient and a substantially linear, i.e. non-crosslinked K-30 to K-120 PVP as a binding agent. The PVP used herein is made by an initiated polymerization process in which vinyl pyrrolidone monomer is polymerized in the presence of an initiator which produces a linear PVP polymerization, i.e. is a poor hydrogen abstractor of PVP polymer backbones, which would produce a disadvantageous crosslinked PVP product. Suitable initiators include low energy peroxyester free radical initiators, such as t-amylperoxy pivalate, an azo initiator, or a redox initiator which can perform at low temperatures. Preferably the residual initiator level in the PVP is reduced to less than 500 ppm, thereby further precluding the possibility of crosslinking of the PVP polymer during the shelf-life of the tablet.